Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Marimed (MRMD) EBIT (2016 - 2025)

Historic EBIT for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to $1.6 million.

  • Marimed's EBIT rose 1888.48% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $724000.0, marking a year-over-year decrease of 8924.7%. This contributed to the annual value of $2.9 million for FY2024, which is 7975.67% down from last year.
  • Latest data reveals that Marimed reported EBIT of $1.6 million as of Q3 2025, which was up 1888.48% from $1.1 million recorded in Q2 2025.
  • Marimed's EBIT's 5-year high stood at $12.0 million during Q2 2021, with a 5-year trough of -$1.2 million in Q4 2024.
  • In the last 5 years, Marimed's EBIT had a median value of $3.1 million in 2022 and averaged $3.5 million.
  • As far as peak fluctuations go, Marimed's EBIT skyrocketed by 59868.15% in 2021, and later plummeted by 14832.02% in 2024.
  • Quarter analysis of 5 years shows Marimed's EBIT stood at $1.2 million in 2021, then soared by 156.77% to $3.1 million in 2022, then fell by 21.95% to $2.4 million in 2023, then tumbled by 148.32% to -$1.2 million in 2024, then surged by 237.25% to $1.6 million in 2025.
  • Its EBIT was $1.6 million in Q3 2025, compared to $1.1 million in Q2 2025 and -$851000.0 in Q1 2025.